NCT07170319Active, not recruitingPhase 1
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 79 (actual)
- First submitted
- 7 Sept 2025
- Start date
- 25 Sept 2025
- Primary completion date
- 24 Dec 2025
- Lead sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Diseases
- Obesity
- NCT number
- NCT07170319
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 79
- From 25 Sept 2025 to the primary completion date, 24 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Other
- Abnormal electrocardiogram (ECG) at screening
Who the study is looking for
- Healthy male or females, as determined by medical history
- Have safety laboratory results within normal reference ranges
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Frist Affiliated Hospital of Anhui Medical University Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.